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Merkel cell carcinoma (MCC) is a rare type of skin
tumor that is derived from epidermal neuroendo-
crine cells. It is an aggressive tumor for which the
5-year survival rate is estimated at 64% for localized
tumors, 39% in cases of regional invasion, and 18%
for metastatic tumors.1 The standard treatment of
the primary tumor is based on surgical resection
with wide margins in conjunction with adjuvant
radiotherapy. At the metastatic stage, in the absence
of consensus, the most commonly proposed
treatment is platinum/etoposide or doxorubicin
chemotherapy, resulting in only a suspensive effect.2
We report the dramatic and sustained response to
imatinib achieved in a patient with inoperable locally
advanced Merkel cell tumor.CASE REPORT
We report the case of a 69-year-old woman with a
MCC of the left eyebrow. This lesion developed
within 3 weeks. It was a 6 cm firm reddish purple
nodule with a central hemorrhagic ulcer (Fig 1, A).
Active and passive palpebral openings were not
possible given the size and infiltration of the tumor.
The diagnosis of MCC was confirmed by histologic
examination. The analysis of exons 11 and 13 of an
the C-KIT gene identified no mutation. CD117 and
platelet-derived growth factor receptor (PDGFR)
staining found a strong expression of PDGFR and
no expression of CD117.
The patient’s medical history included insulin-
dependent diabetes with retinopathy, nephropathy
and neuropathy, hypertension, hypercholesterole-
mia, and a digestive tract hemorrhage from a bulbar
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lighted a mass of 5.33 5.43 4.5 cm with intraorbital
extension at the internal upper quadrant without
osteolysis (Fig 2, A). The thoraco-abdomino-pelvic
CT scan showed no visceral metastasis.
Given the tumor size and location, surgical
resection was refused by the patient because it
would have significant morbidity. Because of anemia
and multiple other comorbidities, chemotherapy
was contraindicated. It was therefore decided during
a multidisciplinary meeting to initiate a treatment
with imatinib in conjunction with radiotherapy.
Imatinib was prescribed at a dose of 400 mg/d.
After 1 month of treatment, before initiation of
radiotherapy, a dramatic clinical response was noted.
The lesionmasswas decreased bymore than 50%, and
the hemorrhage was stopped. Radiotherapy was
cancelled given the excellent response to treatment
and the significant risk of ocular complications.
Four months later, the tumor regression was ongoing
with a complete clinical remission of the entire tumor
(Fig 1, B) and recovery of a palpebral aperture.
This dramatic clinical response was confirmed
on CT scan examination at 6 months and 20 months
(Fig 2, B). The palpebral mass regressed by 40% at 6
months and by 100% at 20 months.
The follow-up was made by fluorodeoxyglucose
positron emission tomography CT. It showed a
progressive decrease of the hypermetabolism ofJAAD Case Reports 2016;2:16-8.
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Fig 1. Evolution of the tumor. A, Large firm tumor of the left eyebrow and impossible palpebral
aperture. B, After 4 months of treatment with imatinib, complete clinical remission of the tumor.
Fig 2. Facial CT scan examination before treatment and after 20 months of imatinib. A,
Voluminous mass with intraorbital extension before treatment. B, Complete remission of the
tumor after 20 months of imatinib.
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intensity on fluorodeoxyglucose positron emission
tomography CT]) after 10 months and 3.36 after
19 months.
The tolerance of the treatment was excellent with
a total absence of clinical and biological adverse
events and an improved general status. After
20 months of treatment, the patient was considered
in complete clinical and radiologic remission and the
treatment was stopped. This complete remission was
maintained after 3 months of follow-up.
DISCUSSION
This case is interesting because of the dramatic
and extremely rapid decrease in tumor mass. In this
patient, imatinib allowed avoiding a damaging
surgery and led to the complete diseapperance of
functional signs despite an initially unfavorable
short-term prognosis.
The complete regression observed might be the
result of spontaneous regression, which is anextremely rare event previously described in
MCC. This hypothesis is unlikely because in the
22 cases reported in the literature of spontaneous
regression of MCC, 15 cases occurred after
incisional biopsy and 7 occurred after local
reccurence.3 In our case, the tumor did not
decrease after biopsy but clearly started to
decrease 7 days after imatinib initiation. Despite
chemotherapy and radiotherapy, therapeutic
failure is common in inoperable MCC, making it
necessary to investigate new treatment options.
Imatinib is a targeted inhibitor of some tyrosine
kinase receptors, including KIT receptor (CD117)
and PDGFR, and it is used for the treatment
of myelodysplastic syndrome, chronic myeloid
leukemia4 and gastrointestinal stromal tumors.5 It is
well tolerated, inducing mainly gastrointestinal
adverse events (nausea and diarrhea) and hemato-
logic toxicity, usually of grade 1 or 2.
Studies show that CD117 and PDGFR are
expressed in MCC, suggesting a potential efficacy
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mutation has been found in the genes encoding
these receptors. In our patient, the analysis of exons
11 and 13 of the C-KIT gene identified no mutation.
The efficacy of the treatment for our patient might be
explained by the strong expression of PDGFR in the
tumor.
A phase II study was initiated in patients with
metastatic or inoperable MCC treatedwith imatinib at
a daily dose of 400 mg. However, the study was
terminated early because of an excessive progres-
sion rate.7
Moreover, 2 isolated cases of inoperable Merkel
cell tumor treated with imatinib were reported in the
literature.8,9 One of the cases was a 92-year-old
woman who had an MCC of the cheek. She received
imatinib 400 mg once daily as first-line treatment
because the tumor stained CD117 and presented a
6-month total remission but died after 6 months of
treatment of another condition. The second case was
a 77-year-old man who had a multifocal MCC of
the scalp, which was not amendable to surgical
treatment or radiation. A first-line treatment with
imatinib was therefore initiated at 400 mg twice a day
for 6 months and then 400 mg once a day for 3
months. The partial response enabled a surgical
excision of the main nodule after 3 months of
treatment. Imatinib was continued, but the patient
presented with a relapse 6 months after surgery,
which was treated by radiotherapy. Our case is rare
in that it has such a significant and rapid response to
imatinib and a sustained efficacy.
Overall, the dramatic efficacy obtained in our
patient, associated with an excellent tolerance,
enables us to consider imatinib as a therapeutic
option for inoperable or metastatic MCC for patientswith contraindications for surgery, radiotherapy, and
chemotherapy or with failure of those treatments.
This observation underlines the need for a clinical
trial comparing cytotoxic chemotherapy and imatinib
in patientswith locally advanced ormetastaticMerkel
cell tumors. It might be necessary to select patients
with PDGFR or CD117 staining, because cases
reported of imatinib efficacy seem to be of patients
who have an overexpression of those receptors.
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